Who is sponsoring NCT04603131?

NCT04603131 is sponsored by Bharat Biotech International Limited.

What drugs are being tested in NCT04603131?

Interventions in NCT04603131: Inactivated Chikungunya virus vaccine 20 mcg, Inactivated Chikungunya virus vaccine 30 mcg, Inactivated Chikungunya virus vaccine 10 mcg, Placebo.

What condition does NCT04603131 study?

NCT04603131 studies Chikungunya.

Is NCT04603131 still recruiting?

NCT04603131 is currently completed. Last updated 28 October 2020.

Last reviewed 2020-10-28 · How we verify

NCT04603131

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Trial to Evaluate the Immunogenicity of Chikungunya Vaccine

Completed Phase 1 Last updated 28 October 2020

What this trial tests

Phase 1 trial testing Inactivated Chikungunya virus vaccine 20 mcg in Chikungunya in 60 participants. Completed in 30 July 2018.

Timeline

17 April 2017

Primary endpoint
30 January 2018

30 July 2018

Quick facts

Lead sponsor	Bharat Biotech International Limited
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	none
Primary purpose	prevention
Enrollment	60
Start date	17 April 2017
Primary completion	30 January 2018
Estimated completion	30 July 2018
Sites	4 locations across India

Drugs / interventions tested

Inactivated Chikungunya virus vaccine 20 mcg — full drug profile →
Inactivated Chikungunya virus vaccine 30 mcg — full drug profile →
Inactivated Chikungunya virus vaccine 10 mcg — full drug profile →
Placebo

Conditions studied

Chikungunya — all drugs for Chikungunya →

Sponsor

Bharat Biotech International Limited — full company profile →

Who can join

Adults 18 to 50, any sex, with Chikungunya. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Chikungunya vaccine is an inactivated virus vaccine. There will be three study arms and subjects will be vaccinated in a dose escalation manner.In each arm, vaccine will be administered on Day 1, Day 29, and Day 57. Vaccine will be administered through intramuscular route.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Developing a Prototype Pathogen Plan and Research Priorities for the Alphaviruses.
Powers AM, Williamson LE, Carnahan RH, Crowe JE, et al · · 2023 · cited 12× · PMID 37849399 · DOI 10.1093/infdis/jiac326
Resurgence of Chikungunya virus: rising global threat and challenges in its mitigation.
Sahu PS, Pattnaik R, Alissa M, Abusalim GS, et al · · 2026 · PMID 42100311 · DOI 10.3389/fphar.2026.1757035

Verify or expand the search:

Other recruiting trials for Chikungunya

Currently open trials in the same condition.

NCT07358910 — Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective · recruiting
NCT04619823 — Virological and Immunological Determinants of Arbovirus Infection in New Caledonia · NA · recruiting
NCT04615364 — Genetic Evolution of Arboviruses in New Caledonia Between 1995 and 2024 and Impact of Wolbachia · recruiting

Other Bharat Biotech International Limited trials

Trials by the same sponsor.

NCT06997367 — Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine MTBVAC in Healthy Indian Adults and Adolescents (BBV16 · Phase 2 · active not recruiting
NCT06438978 — Tuberculosis Vaccine in Healthy Indian Adults · Phase 1 · completed
NCT05522335 — Phase III Study of BBV154 Intranasal Vaccine in Healthy Volunteers · Phase 3 · unknown
NCT05567471 — Phase 3 Study to Evaluate Immunogenicity and Safety of BBV154 Booster Dose · Phase 3 · completed
NCT05507229 — A Phase III Randomized, Modified Double-blind, Multi-centric, Comparative Study, to Evaluate the Non-inferiority of Immu · Phase 3 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04603131 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bharat Biotech International Limited
Last refreshed: 28 October 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04603131.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing